secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-104164
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025
--------------------------------------------------------------------------------

- Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.
- Cash, equivalents and marketable securities $71.7M as of June 30, 2025; runway into H2 2026.
- TN-201 for HCM: Cohorts 1 & 2 enrollment complete; DSMB allows expansion; data readout Q4 2025.
- TN-401 for ARVC: Cohort 1 enrolled; DSMB recommends dose escalation; first patient dosed in Cohort 2; data Q4 2025.
- R&D expense $17.4M vs $22.6M YoY; G&A $6.7M vs $8.2M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017025104164/0000950170-25-104164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017025104164/tnya-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer